Company Overview of Celtaxsys, Inc.
Celtaxsys, Inc., a biopharmaceutical company, engages in developing and testing drug compounds for treating cancer, and inflammatory and autoimmune diseases. Its technology manipulates immune cell migration as a treatment for cancer, inflammation, and organ/tissue rejection. The company’s drug compounds are designed to block the protective mechanisms created by certain tumors to prevent attack by immune system cells. Celtaxsys, Inc. was founded in 2007 and is based in Atlanta, Georgia.
311 Ferst Drive
Atlanta, GA 30332
Founded in 2007
Key Executives for Celtaxsys, Inc.
Founder and Chief Financial Officer
Chairman of Medical Advisory Panel and Chief Medical Officer
Compensation as of Fiscal Year 2014.
Celtaxsys, Inc. Key Developments
Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer
Nov 6 14
Celtaxsys, Inc. announced the appointment of Sanjeev Ahuja, MD, MBA, FACP as Chief Medical Officer, effective November 1, 2014. Sanjeev most recently Chief Medical Officer at On Target Laboratories.
Celtaxsys, Inc. Appoints Greg Duncan as President and Chief Executive Officer
Jan 8 14
The Celtaxsys Board of Directors announced that Greg Duncan has been appointed as President and Chief Executive Officer (CEO) and will join the board of directors effective immediately. Mr. Duncan joins the company following his most recent role as an Executive Committee member and President of North America for Brussels based UCB, prior to which he served as a Senior Vice-President at Pfizer where his duties included leading US marketing, as well as President of their Latin America operations. Greg will be based in Atlanta, Georgia. Greg most recently served as an Executive Vice President at UCB, a member of UCB's Executive Committee, and President of North American Operations for UCB, Inc.
Celtaxsys, Inc. Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients
Oct 10 13
Celtaxsys, Inc. announced it is now enrolling patients for its first trial of CTX-4430 oral treatment for lung disease in Cystic Fibrosis patients. In this study, the safety and tolerability of CTX-4430 will be assessed at several dose levels when administered orally once-daily for 2 weeks. Additional assessments will include pharmacokinetics and biomarkers, as well as effects on lung function. This first CF study will be conducted at three sites in the U.K. under the oversight of Professor Stuart Elborn, MD, of Queens University, Belfast, and is slated to test four dose levels of oral once-daily CTX-4430 treatment in 36 adult CF patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|